266 related articles for article (PubMed ID: 33157193)
1. The emerging nature of Ubiquitin-specific protease 7 (USP7): a new target in cancer therapy.
Nininahazwe L; Liu B; He C; Zhang H; Chen ZS
Drug Discov Today; 2021 Feb; 26(2):490-502. PubMed ID: 33157193
[TBL] [Abstract][Full Text] [Related]
2. Targeting ubiquitin specific protease 7 in cancer: A deubiquitinase with great prospects.
Yeasmin Khusbu F; Chen FZ; Chen HC
Cell Biochem Funct; 2018 Jul; 36(5):244-254. PubMed ID: 29781103
[TBL] [Abstract][Full Text] [Related]
3. USP7: Target Validation and Drug Discovery for Cancer Therapy.
Zhou J; Wang J; Chen C; Yuan H; Wen X; Sun H
Med Chem; 2018; 14(1):3-18. PubMed ID: 29065837
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the development of ubiquitin-specific-processing protease 7 (USP7) inhibitors.
Li P; Liu HM
Eur J Med Chem; 2020 Apr; 191():112107. PubMed ID: 32092586
[TBL] [Abstract][Full Text] [Related]
5. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.
Schauer NJ; Liu X; Magin RS; Doherty LM; Chan WC; Ficarro SB; Hu W; Roberts RM; Iacob RE; Stolte B; Giacomelli AO; Perera S; McKay K; Boswell SA; Weisberg EL; Ray A; Chauhan D; Dhe-Paganon S; Anderson KC; Griffin JD; Li J; Hahn WC; Sorger PK; Engen JR; Stegmaier K; Marto JA; Buhrlage SJ
Sci Rep; 2020 Mar; 10(1):5324. PubMed ID: 32210275
[TBL] [Abstract][Full Text] [Related]
6. Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies.
Wu J; Kumar S; Wang F; Wang H; Chen L; Arsenault P; Mattern M; Weinstock J
J Med Chem; 2018 Jan; 61(2):422-443. PubMed ID: 28768102
[TBL] [Abstract][Full Text] [Related]
7. USP7 small-molecule inhibitors interfere with ubiquitin binding.
Kategaya L; Di Lello P; Rougé L; Pastor R; Clark KR; Drummond J; Kleinheinz T; Lin E; Upton JP; Prakash S; Heideker J; McCleland M; Ritorto MS; Alessi DR; Trost M; Bainbridge TW; Kwok MCM; Ma TP; Stiffler Z; Brasher B; Tang Y; Jaishankar P; Hearn BR; Renslo AR; Arkin MR; Cohen F; Yu K; Peale F; Gnad F; Chang MT; Klijn C; Blackwood E; Martin SE; Forrest WF; Ernst JA; Ndubaku C; Wang X; Beresini MH; Tsui V; Schwerdtfeger C; Blake RA; Murray J; Maurer T; Wertz IE
Nature; 2017 Oct; 550(7677):534-538. PubMed ID: 29045385
[TBL] [Abstract][Full Text] [Related]
8. A patent review of ubiquitin-specific protease 7 (USP7) inhibitors (2014-present).
Li P; Liu Y; Liu HM
Expert Opin Ther Pat; 2022 Jul; 32(7):753-767. PubMed ID: 35343357
[TBL] [Abstract][Full Text] [Related]
9. Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy.
Harakandi C; Nininahazwe L; Xu H; Liu B; He C; Zheng YC; Zhang H
Bioorg Chem; 2021 Nov; 116():105273. PubMed ID: 34474304
[TBL] [Abstract][Full Text] [Related]
10. Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth.
Li X; Kong L; Yang Q; Duan A; Ju X; Cai B; Chen L; An T; Li Y
J Biol Chem; 2020 Mar; 295(11):3576-3589. PubMed ID: 32029476
[TBL] [Abstract][Full Text] [Related]
11. USP7-Specific Inhibitors Target and Modify the Enzyme's Active Site via Distinct Chemical Mechanisms.
Pozhidaeva A; Valles G; Wang F; Wu J; Sterner DE; Nguyen P; Weinstock J; Kumar KGS; Kanyo J; Wright D; Bezsonova I
Cell Chem Biol; 2017 Dec; 24(12):1501-1512.e5. PubMed ID: 29056420
[TBL] [Abstract][Full Text] [Related]
12. An Integrated in silico Approach and in vitro Study for the Discovery of Small-Molecule USP7 Inhibitors as Potential Cancer Therapies.
Kanan D; Kanan T; Dogan B; Orhan MD; Avsar T; Durdagi S
ChemMedChem; 2021 Feb; 16(3):555-567. PubMed ID: 33063944
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin-specific protease 7 (USP7): an emerging drug target for cancer treatment.
Carreira LD; Oliveira RI; Moreira VM; Salvador JAR
Expert Opin Ther Targets; 2023; 27(11):1043-1058. PubMed ID: 37789645
[TBL] [Abstract][Full Text] [Related]
14. USP7: Structure, substrate specificity, and inhibition.
Pozhidaeva A; Bezsonova I
DNA Repair (Amst); 2019 Apr; 76():30-39. PubMed ID: 30807924
[TBL] [Abstract][Full Text] [Related]
15. Characterization of naturally occurring pentacyclic triterpenes as novel inhibitors of deubiquitinating protease USP7 with anticancer activity in vitro.
Jing B; Liu M; Yang L; Cai HY; Chen JB; Li ZX; Kou X; Wu YZ; Qin DJ; Zhou L; Jin J; Lei H; Xu HZ; Wang WW; Wu YL
Acta Pharmacol Sin; 2018 Mar; 39(3):492-498. PubMed ID: 29168472
[TBL] [Abstract][Full Text] [Related]
16. Active site-targeted covalent irreversible inhibitors of USP7 impair the functions of Foxp3+ T-regulatory cells by promoting ubiquitination of Tip60.
Wang F; Wang L; Wu J; Sokirniy I; Nguyen P; Bregnard T; Weinstock J; Mattern M; Bezsonova I; Hancock WW; Kumar S
PLoS One; 2017; 12(12):e0189744. PubMed ID: 29236775
[TBL] [Abstract][Full Text] [Related]
17. Targeting the deubiquitinase USP7 for degradation with PROTACs.
Murgai A; Sosič I; Gobec M; Lemnitzer P; Proj M; Wittenburg S; Voget R; Gütschow M; Krönke J; Steinebach C
Chem Commun (Camb); 2022 Aug; 58(63):8858-8861. PubMed ID: 35852517
[TBL] [Abstract][Full Text] [Related]
18. Discovery of USP7 small-molecule allosteric inhibitors.
Engström O; Belda O; Kullman-Magnusson M; Rapp M; Böhm K; Paul R; Henderson I; Derbyshire D; Karlström S; Parkes KEB; Zhao H
Bioorg Med Chem Lett; 2020 Oct; 30(20):127471. PubMed ID: 32781219
[TBL] [Abstract][Full Text] [Related]
19. USP7 manipulation by viral proteins.
Bojagora A; Saridakis V
Virus Res; 2020 Sep; 286():198076. PubMed ID: 32603670
[TBL] [Abstract][Full Text] [Related]
20. Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7.
Lamberto I; Liu X; Seo HS; Schauer NJ; Iacob RE; Hu W; Das D; Mikhailova T; Weisberg EL; Engen JR; Anderson KC; Chauhan D; Dhe-Paganon S; Buhrlage SJ
Cell Chem Biol; 2017 Dec; 24(12):1490-1500.e11. PubMed ID: 29056421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
